Time to renew the antibiotic arsenal
19 January 2016 | By Philippe Villain-Guillot, CEO, Nosopharm
Philippe Villain-Guillot, CEO, Nosopharm, discusses antimicrobial resistance and the challenges facing antibacterial drug discovery and development...
List view / Grid view
News
Rapastinel demonstrates pro-cognitive benefits in animal model of cognitive impairment
19 January 2016 | By Victoria White
Allergan has announced new data on the investigational medication rapastinel (GLYX-13) and its lack of impairment on cognitive function...
Breast cancer study reveals new drug targets and combinations
19 January 2016 | By Victoria White
The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations...
UCL announces new £50 million fund to commercialise research
18 January 2016 | By Victoria White
The Fund will be used to support academics whose research has commercial potential, with funding for early stage proof of concept, licensing projects and new spinout companies...
F-star and AbbVie to develop bispecific antibodies in immuno-oncology
18 January 2016 | By Victoria White
Under the collaboration agreement, F-star and AbbVie will create Fcabs against two immuno-oncology targets and generate several mAb2 drug development candidates from these Fcabs...
Centauri acquires Alphamer technology from Altermune
18 January 2016 | By Victoria White
Centuari has also announced that it has appointed Dr Clive Dix as Chairman and secured the first tranche of a £3M raise to develop its first lead candidate...
Channel-blocker drug helps restore vision in mice with optic nerve injury
14 January 2016 | By Victoria White
Researchers were able to restore vision in mice by using gene therapy to get the nerves to regenerate and adding a channel-blocking drug to help the nerves conduct impulses...
Calibr and Pfizer to develop heart failure therapies
14 January 2016 | By Victoria White
Calibr's antibody fusion technology provides a proprietary, modular approach to developing long-acting biotherapeutics based on peptide and protein agonists and antagonists...
Sanofi Pasteur announces support for the Human Vaccines Project
14 January 2016 | By Victoria White
The Human Vaccines Project is a research programme designed to accelerate the development of vaccines by decoding the human immune system...
Researchers discover previously unknown defect in Parkinson’s disease
13 January 2016 | By Victoria White
The discovery, made by BUSM scientists, may lead to a better understanding of the disease, early diagnosis and therapeutic development...
XBP-1 pathway plays key role in CF airway inflammation
13 January 2016 | By Victoria White
Researchers have discovered that the XBP-1 pathway was implicated in the hyper-inflammatory response of cystic fibrosis alveolar macrophages...
Registration has now opened for Oxford Global’s 17th Annual Drug Discovery Leaders Summit
13 January 2016 | By Oxford Global
Oxford Global Conferences are proud to present the successful 17th Annual Drug Discovery Leaders Summit and co-located 4th Annual Discovery Chemistry & Drug Design Congress taking place on the 13th & 14th June in Berlin...
Antibodies zap both EBOV and SUDV Ebola strains
13 January 2016 | By Victoria White
Researchers have engineered the first antibodies that can potently neutralise the two deadliest strains of the virus that causes Ebola haemorrhagic fever...
An interview with Bernardo Perez-Ramirez, Sanofi, speaker at the 9th Annual Proteins & Antibodies Congress, 18-19 April 2016, London, UK
13 January 2016 | By Oxford Global
In anticipation of our Proteins and Antibodies Congress, Bernardo Perez-Ramirez spoke to us about his research and his expectations...
An interview with Elaine Pinheiro, Principal Scientist at MSD, speaker at the Advances in Immuno-oncology Congress, 12-13 May 2016, London, UK
13 January 2016 | By Oxford Global
Ahead of the Advances in Immuno-oncology Congress, we spoke to Elaine Pinheiro, Principal Scientist at MSD about her group’s work and where the industry is moving at the moment...